Sign in

CIK 0001158780

  • Non-accelerated filer
  • Smaller reporting company
Ticker
PLUR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Jun 30
Incorporated
NV
Entity type
Operating
EIN
980351734
Phone
+972 747107171
Business address
MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA, Israel
Former names
PLURISTEM THERAPEUTICS INC, PLURISTEM LIFE SYSTEMS INC, AI SOFTWARE INC
  1. 4 Open-market buy Director bought 12,346 shares at $0.81 ($9,968)
  2. 4 Open-market buy Director bought 10,000 shares at $0.79 ($7,900)
  3. 4 Open-market buy CFO, COO & President bought 5,000 shares at $0.83 ($4,139)
  4. 4 Open-market buy CEO & Chairman bought 31,000 shares at $0.80 ($24,716)
  5. 4 Grant or award Director acquired 49,000 shares (grant or award)
  6. 4 Grant or award CEO & Chairman acquired 150,000 shares (grant or award)
  7. 4 Grant or award CFO, COO & President acquired 150,000 shares (grant or award)
  8. 4 Grant or award Director acquired 49,000 shares (grant or award)
  9. 4 Grant or award Director acquired 35,000 shares (grant or award)
  10. 4 Grant or award Director acquired 48,000 shares (grant or award)
  11. 4 Grant or award Director acquired 35,000 shares (grant or award)
  12. 4 Grant or award Director acquired 35,000 shares (grant or award)
  13. 4 Grant or award Director acquired 49,000 shares (grant or award)
  14. 4 Open-market buy CEO & Chairman bought 9,900 shares at $1.49 ($14,751)
  15. 4 Open-market buy CFO, COO & President bought 10,000 shares at $1.52 ($15,200)
  16. 4 Open-market sale Director sold 30,000 shares at $2.10 ($63,000)
  17. 4 Open-market buy CFO, COO & President bought 10,000 shares at $2.11 ($21,100)
  18. 4 Open-market buy CEO & Chairman bought 25,500 shares at an average $2.11 ($53,780)
  19. 4 Open-market buy COO, CFO & President bought 10,000 shares at an average $2.12 ($21,155)
  20. 4 Open-market buy CEO & Chairman bought 25,000 shares at an average $2.11 ($52,750)

Page 7 of 18 · 352 filings